BioDay
BioDay Registry...
Description
The BioDay registry is a disease or condition registry for atopic dermatitis (AD)/prurigo nodularis (PN). All patients treated with advanced systemic therapy (biologics and JAK inhibitors [JAKi]) for AD are eligible for inclusion in the prospective, ...
General Design
- Cohort type
Registry
- Design
Longitudinal
- Design description
Multicenter prospective observational atopic dermatitis registry
- Collection type
Prospective
- Start/End year
2017 - ongoing
Population
- Countries
Netherlands (the)
- Regions
Limburg, Zeeland, Zuid-Holland, Noord-Holland, Noord-Brabant, Flevoland, Utrecht, Gelderland, Overijssel, Friesland, Groningen
- Number of participants
2000
- Population age groups
All ages
- Main medical condition
- XII Diseases of the skin and subcutaneous tissue
- L20-L30 Dermatitis and eczema
- L20 Atopic dermatitis
- L20.8 Other atopic dermatitis
- L20.9 Atopic dermatitis, unspecified
- L30.1 Other dermatitis - Dyshidrosis [pompholyx]
- L30.9 Dermatitis, unspecified
- L20.0 Atopic dermatitis - Besnier prurigo
- L28.1 Prurigo nodularis
- Inclusion criteria
- Defined population inclusion criterion
- Use of medication inclusion criterion
- Other inclusion criteria
Able and willing to sign informed consent form
Contributors
Lead organisation
- UMC Utrecht
- University Medical Center Groningen
Contributors
- prof. dr. Marjolein de Bruin-Weller
- dr. Inge Haeck
- dr. Marlies de Graaf
- dr. Marie-Louise Schuttelaar
Additional organisations
- Maastricht UMC+
- Radboud universitair medisch centrum
- Wilhelmina Kinderziekenhuis
- Spaarne Gasthuis
- Meander Medisch Centrum
- HagaZiekenhuis
- St. Antonius Hospital
- Catharina Hospital
- IJsselland Hospital
- Medical Centre Leeuwarden
- Isala Hospital
- Tergooi hospital
- Bravis hospital
- ZorgSaam hospital
- Ziekenhuis Tjongerschans
Available Data & Samples
Data categories
- Biological samples
- Survey data
- Imaging data
- Medical records
- Physiological/Biochemical measurements
- Other
Areas of information
- Lifestyle and behaviours
- Sleep
- Tobacco
- Alcohol
- Drugs
- Birth, pregnancy and reproductive health history
- Contraception
- Perception of health, quality of life, development and functional limitations
- Perception of health
- Quality of life
- Symptoms and signs
- Symptoms and signs involving the skin and subcutaneous tissue (R20-R23)
- Medication and supplements
- Medication and supplement intake
- Health and community care services utilization
- Hospitalizations
- Death
- Vital status
- Cause of death
- Physical measures and assessments
- Physical characteristics
- Skin and subcutaneous tissue
- Anthropometry
- Laboratory measures
- Hematology
- Biochemistry
- Immunology
- Microbiology
- Virology
- Non-pharmacological interventions
- Surgical interventions
- Cognition, personality and psychological measures and assessments
- Other psychological measures and assessments
- Socio-demographic and economic characteristics
- Age/birthdate
- Sex/gender
- Education
- Ethnicity, race and religion
- Labour force and retirement
Subpopulations
List of subcohorts or subpopulations for this resource...
| Name | Description | Number of participants |
|---|
Collection events
List of collection events defined for this resource...
| Name | Description | Participants | Start end year |
|---|
Partners
Networks
List of networks in which this cohort is involved...
Publications
Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry
Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis
Long-term Results From the Daily Practice BioDay Registry
Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry
Dupilumab-Associated Lymphoid Reactions in Patients With Atopic Dermatitis
Early qualitative and quantitative amplitude-integrated electroencephalogram and raw electroencephalogram for predicting long-term neurodevelopmental outcomes in extremely preterm infants in the Netherlands: a 10-year cohort study
Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry
Muscle and joint pain during dupilumab treatment for atopic dermatitis: Lack of association with antinuclear antibodies
Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry
Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry
The positive effect of dupilumab on comorbid asthma in patients with atopic dermatitis
Access conditions
Possible approval after data access request...
- Data access conditions
- health or medical or biomedical research
- disease specific research
- Data use conditions
- not for profit, non commercial use only
- collaboration required
- user specific restriction
- project specific restriction
- Release type
- Periodically
- Release description
Quarterly data-locks are in place.
Funding & Acknowledgements
- Funding
The BioDay Registry is sponsored by pharmaceutical companies of the biologicals and JAKi for AD (Sanofi Genzyme/Regeneron, Leo Pharma, Pfizer and Eli Lilly). These commercial sponsors do not have any influence on the collection and analyses of the data in the register.